In a release on
-The Company will also allow patients who are currently in the screening process to enroll in the Abili-T clinical study should they meet the trial's entry criteria. The Company expects to report the top-line results of the Abili-T clinical study in mid-2016.
-In March, Opexa appointed two highly experienced individuals to join the Company's Board of Directors -
-Reported cash and cash equivalents of
-Opexa believes it has sufficient liquidity to support its current clinical activities for the Abili-T trial and general operations to sustain the Company and support such trial into the fourth quarter of 2015.
"Reaching our clinical trial enrollment target of 180 patients in the Phase IIb Abili-T trial in Secondary Progressive Multiple Sclerosis represents an important milestone in the development of our personalized immunotherapy for this unmet medical need," said
During the first quarter of 2014,
First Quarter Financial Results
Opexa reported revenue of
Research and development expenses were
General and administrative expenses for the three months ended
Depreciation and amortization expenses for the three months ended
Interest expense of
Opexa reported a net loss for the three months ended
Cash and cash equivalents were
For additional information please see Opexa's Quarterly Report on Form 10-Q filed
Opexa conducted a conference call and webcast to provide a corporate update and discuss the financial results on
Opexa's mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Company's leading therapy candidate, Tcelna, is a personalized T- cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient's peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections.
((Comments on this story may be sent to firstname.lastname@example.org))
In a release on